Index

Note: Page numbers of article titles are in **boldface** type.

A

Adhesiolysis
  in revisional bariatric surgery, 1355
Adjustable gastric banding (AGB)
  complications of, **1249–1264**
    early postoperative, 1250–1252
      cardiac, 1251
      obstructive, 1251–1252
      pulmonary, 1250–1251
    intraoperative, 1250
    late postoperative, 1252–1260
      adjustable gastric band failure, 1259–1260
      adjustment difficulty, 1258–1259
      erosion, 1256–1257
      esophageal failure, 1253–1254
      GERD, 1253
      port and tubing, 1252–1253
      pouch dilation, 1254
      weight loss failure, 1257–1258
  laparoscopic, **1239–1247**. *See also* Laparoscopic adjustable gastric banding (LAGB)
  LSG *vs.*
    comparative effectiveness studies on, 1329
  mortality rates with, 1249
  revision after, 1363–1366
  RYGB *vs.*
    comparative effectiveness studies on, 1327–1328
Adolescent(s)
  bariatric surgery in, **1339–1351**
    ethical issues related to, 1347–1348
    indications for, 1342–1344
    IPEG guidelines for, 1342–1343
    outcomes of, 1344–1347
  obesity in
    behavioral and medical therapy for, 1341–1342
    demographics of, 1339–1340
    health impact of, 1340–1341
AGB. *See* Adjustable gastric banding (AGB)
Anastomotic leaks
  LRNYGB and, 1226–1228
Anastomotic strictures
  LRNYGB and, 1233–1234

Surg Clin N Am 91 (2011) 1397–1408
doi:10.1016/S0039-6109(11)00137-X
surgical.theclinics.com

0039-6109/11/$ – see front matter © 2011 Elsevier Inc. All rights reserved.

Asthma
bariatric surgery and, 1301
Atherosclerosis
bariatric surgery and, 1300

B

Bariatric surgery. *See also* Bariatric surgery procedures; Weight loss surgery
in adolescents, **1339–1351**. *See also* Adolescent(s), bariatric surgery in
comorbidities related to, **1295–1312**
asthma, 1301
atherosclerosis, 1300
cancer, 1304
cardiovascular disorders, 1299–1300
congestive heart failure, 1299–1300
coronary artery disease, 1300
diabetes mellitus type 2, 1296–1297
digestive disorders, 1302–1303
hyperlipidemia, 1298–1299
hypertension, 1297–1298
intracranial hypertension, 1304
menstrual disorders, 1303–1304
musculoskeletal disorders, 1303
neurologic disorders, 1303–1304
OSA, 1301
psychological disorders, 1303–1304
renal disorders, 1301–1302
sexual disorders, 1303–1304
economic costs of obesity and, **1173–1180**
enteroencephalic endocrine axis communication pathways effects on, 1151
enteroinsular axis effects on, 1154–1155
evolution of, 1373–1376
current procedures in, 1376–1377
digestive adaptation, 1376–1377
gastric plication, 1377
ileal interposition, 1376–1377
future directions in, **1373–1395**
ghrelin effects of, 1151–1152
glucagon-like peptide-1 effects on, 1155
glucose-independent insulinotropic peptide effects on, 1155
incretin effect in, 1155–1157
indications for, 1377–1379
laparoscopy in, 1197
leptin effects of, 1154
mortality associated with, 1314–1317
new techniques, 1379–1383
NOTES, 1380–1381
robotics, 1381–1383
single-incision laparoscopy, 1379–1380
outcomes of, **1313–1338**
comparative effectiveness studies on, 1326–1329

comparison among procedures, 1319–1320
early complications
patient characteristics influencing, 1326
health care cost impact, 1330–1331
importance of, 1313–1314
LAGB, 1323–1324
laparoscopic BPD/DS, 1325
life expectancy/long-term survival advantage improvement, 1329–1330
LRNYGB, 1320–1321
LSG, 1324–1325
mortality-related, 1314–1317
quality of life, 1330
risk factors associated with
understanding of, 1313–1314
weight loss–related, 1317–1319
peptide YY effects of, 1153
prevalence of, 1225
procedures for. *See also specific procedures and* Bariatric surgery procedures
revisional, **1353–1371**. *See also* Revisional bariatric surgery
Bariatric surgery procedures. *See also specific procedures*
BPD, 1183–1185
comparison among
outcome-related, 1319–1320
endoscopic, 1383–1388
endoluminal sleeve, 1384–1386
endoscopic suturing platforms, 1386–1388
gastric pacing, 1386
intragastric balloon, 1383–1384
history and evolution of, **1181–1201**
malabsorptive procedures, 1181–1183
malabsorptive procedures with restrictive procedures, 1183–1189
malabsorptive procedures, 1181–1183
jejunoileal bypass, 1181–1183
with restrictive procedures, 1183–1189
revision after, 1366–1367
restrictive procedures, 1189–1197
failed
revision after, 1361–1366
gastric band, 1192–1195
gastroplasty, 1189–1192
with malabsorptive procedures, 1183–1189
sleeve gastrectomy, 1195–1197
BIB. *See* BioEnterics intragastric balloon (BIB)
Biliopancreatic diversion with duodenal switch (BPD-DS), **1281–1293,** 1374
evolution of, 1185–1187
history of, 1185–1187, 1281–1282
indications for, 1284–1285
laparoscopic
complications of, 1325–1326
outcomes of, 1325
physiologic basis of, 1282–1284

Biliopancreatic (*continued*)
results of, 1288–1290
technique, 1285–1288
Biliopancreative diversion (BPD)
history and evolution of, 1183–1185
BioEnterics intragastric balloon (BIB), 1383
Bleeding
GI
LRNYGB and, 1228–1229
BMI. *See* Body mass index (BMI)
Body mass index (BMI)
in obesity, 1163–1164
BPD. *See* Biliopancreatic diversion (BPD)
BPD-DS. *See* Biliopancreatic diversion with duodenal switch (BPD-DS)

C

Cancer
bariatric surgery and, 1304
Cardiovascular disorders
bariatric surgery and, 1299–1300
Children
obesity in
behavioral and medical therapy for, 1341–1342
demographics of, 1339–1340
health impact of, 1340–1341
Cholelithiasis
LRNYGB and, 1213
Congestive heart failure
bariatric surgery and, 1299–1300
Contrast upper GI study
in revisional bariatric surgery evaluation, 1354
Coronary artery disease
bariatric surgery and, 1300

D

Death
LRNYGB and, 1212
Diabetes mellitus type 2
bariatric surgery effects on, 1154–1155, 1296–1297
causes of, 1140
described, 1140–1141
economic impact of, 1167
enteroinsular axis effects of, 1154–1155
epidemic of, 1166–1167
epidemiology of, **1166–1168**
incretin effect and, 1155–1157
management of, 1168–1169
obesity and, 1139–1140
described, 1144–1145
pathophysiology of, **1139–1148**
prevalence of, 1139

Dietary intake diary and nutritional counseling
in revisional bariatric surgery evaluation, 1354
Digestive adaptation, 1376–1377
Digestive disorders
bariatric surgery and, 1302–1303
Drains
in revisional bariatric surgery, 1356
Dumping syndrome
LRNYGB and, 1215
Duodenal switch
BPD with, **1281–1293**. *See also* Biliopancreatic diversion with duodenal switch (BPD-DS)

E

Eagle Claw endoscopic suturing device, 1386–1387
Embolism
pulmonary
LRNYGB and, 1212
EndoBarrier gastrointestinal liner, 1384–1385
EndoCinch Suturing System, 1387
Endoluminal sleeve, 1384–1386
Endoscopic suturing platforms, 1386–1388
Endoscopy
upper
in revisional bariatric surgery evaluation, 1354
Enteroencephalic endocrine axis
communication pathways of
bariatric surgery effects on, 1151
Enteroinsular axis
bariatric surgery effects on, 1154–1155
diabetes mellitus type 2 effects on, 1154–1155
Erosion
AGB and, 1256–1257
Esophageal failure
AGB and, 1253–1254
late postoperative
slippage/prolapse, 1254–1256
Esophageal manometry
in revisional bariatric surgery evaluation, 1354–1355
Ethical issues
adolescent bariatric surgery–related, 1347–1348

G

Garren-Edwards bubble (GEB), 1383
Gastrectomy
sleeve, **1265–1279**. *See also* Sleeve gastrectomy
Gastric band
history and evolution of, 1192–1195
Gastric banding
history of, 1240

Gastric bypass
history and evolution of, 1187–1189
Gastric pacing, 1386
Gastric plication
described, 1377
Gastric stapling
in revisional bariatric surgery, 1355
Gastroesophageal reflux disease (GERD)
AGB and, 1253
Gastrointestinal (GI) bleeding
LRNYGB and, 1228–1229
Gastroplasty
history and evolution of, 1189–1192
Gastrostomy tube
in revisional bariatric surgery, 1356
GEB. *See* Garren-Edwards bubble (GEB)
Genetics
in obesity, 1143
GERD. *See* Gastroesophageal reflux disease (GERD)
Ghrelin
bariatric surgery effects on, 1151–1152
GI. *See* Gastrointestinal (GI)
Glucagon-like peptide-1
bariatric surgery effects of, 1155
Glucose-independent insulinotropic peptide
bariatric surgery effects of, 1155

H

Health care costs
bariatric surgery effects on, 1330–1331
Hernia(s)
internal
LRNYGB and, 1213, 1229
Hyperinsulinemic hypoglycemia
LRNYGB and, 1215–1216
Hyperlipidemia
bariatric surgery and, 1298–1299
Hypertension
bariatric surgery and, 1297–1298
intracranial
bariatric surgery and, 1304
Hypoglycemia
hyperinsulinemic
LRNYGB and, 1215–1216

I

Ileal interposition, 1376–1377
Incretin effect
diabetes mellitus type 2 effects of, 1155–1157

Internal hernia
LRNYGB and, 1213, 1229
International Pediatric Endosurgery Group (IPEG)
guidelines for bariatric surgery in adolescents, 1342–1343
Intestinal leaks
LRNYGB and, 1212
Intestinal obstruction
LRNYGB and, 1230–1231
Intracranial hypertension
bariatric surgery and, 1304
Intragastric balloon, 1383–1384
IPEG. *See* International Pediatric Endosurgery Group (IPEG)

J

Jejunoileal bypass
history and evolution of, 1181–1183

L

LAGB. *See* Laparoscopic adjustable gastric banding (LAGB)
LAP-BAND
history of, 1240
Laparoscopic adjustable gastric banding (LAGB)
comorbidities associated with
resolution of, 1243
complications of, 1324
described, 1239
evolution of, **1239–1247**
intraoperative care, 1241–1242
outcomes of, 1242–1243, 1323–1324
short- and long-term, 1242
weight loss–related, 1242–1243
placement of
surgical technique, 1240–1241
postoperative care, 1241–1242
preoperative care, 1241–1242
Laparoscopic biliopancreatic diversion with or without duodenal switch (BPD-DS)
complications of, 1325–1326
outcomes of, 1325
Laparoscopic Roux-en-Y gastric bypass (LRNYGB)
complications of, 1211–1216, **1225–1237,** 1321–1322
anastomotic leaks, 1226–1228
anastomotic strictures, 1233–1234
bypassed stomach dilatation, 1214
cholelithiasis, 1213
death, 1212
dumping syndrome, 1215
GI bleeding, 1228–1229
hyperinsulinemic hypoglycemia, 1215–1216
inadequate weight loss, 1214
internal hernia, 1213, 1229

Laparoscopic (*continued*)
intestinal leaks, 1212
intestinal obstruction, 1230–1231
marginal ulcers, 1213–1214, 1231–1233
nutritional, 1216–1218
pulmonary embolism, 1212
stomal stenosis, 1213
venous thromboembolism, 1226
wound-related, 1214
current techniques, 1207–1210
analysis of, 1210–1211
linear-stapled technique, 1210
transoral circular-stapled technique, 1208–1209
described, 1225
evolution of, 1203–1207
for morbid obesity, **1203–1224**
mortality rates with, 1249
outcomes of, 1320–1321
Laparoscopic Roux-en-Y linear-stapled technique, 1210
Laparoscopic Roux-en-Y transoral circular-stapled technique, 1208–1209
Laparoscopic sleeve gastrectomy (LSG)
AGB *vs.*
comparative effectiveness studies on, 1329
complications of, 1325
outcomes of, 1324–1325
RYGB *vs.*
comparative effectiveness studies on, 1328–1329
Laparoscopy
in bariatric surgery, 1197
single-incision, 1379–1380
Leak testing
in revisional bariatric surgery, 1355–1356
Leptin
bariatric surgery effects of, 1154
Loop gastric bypass
conversion to RYGB, 1357–1358
LRNYGB. *See* Laparoscopic Roux-en-Y gastric bypass (LRNYGB)
LSG. *See* Laparoscopic sleeve gastrectomy (LSG)

M

Manometry
esophageal
in revisional bariatric surgery evaluation, 1354–1355
Marginal ulcers
LRNYGB and, 1213–1214, 1231–1233
Menstrual disorders
bariatric surgery and, 1303–1304
Metabolic syndrome, 1141–1142
Metformin
for obesity in adolescents, 1342

Mineral deficiencies
after LRNYGB, 1216–1218
Musculoskeletal disorders
bariatric surgery and, 1303

N

Natural orifice transluminal endoscopic surgery (NOTES), 1380–1381
Neurologic disorders
bariatric surgery and, 1303–1304
Neuropeptide Y
bariatric surgery effects on, 1152–1153
NOTES. *See* Natural orifice transluminal endoscopic surgery (NOTES)
Nutrition
complications after LRNYGB, 1216–1218

O

Obesity
BMI criteria for, 1163–1164
childhood
behavioral and medical therapy for, 1341–1342
demographics of, 1339–1340
health impact of, 1340–1341
defined, 1141, 1163
described, 1139
diabetes mellitus type 2 and, 1139–1140
described, 1144–1145
pathophysiologic connection between, 1167–1168
diseases associated with, 1173–1174
economic impact of, 1139, 1166
bariatric surgery effects on, **1173–1180**
described, 1173–1176
epidemic of, 1165–1166
epidemiology of, **1163–1166**
factors leading to, 1141–1143
familial component in, 1143
genetic defects in, 1143
hypotheses and theories about, 1149–1150
management of, 1168–1169
morbid
prevalence of, 1313
surgical treatment for
LRNYGB in, **1203–1224**. *See also* Laparoscopic Roux-en-Y gastric bypass (LRNYGB)
morbidity and mortality related to, 1164–1165
pathophysiology of, **1139–1148**
prevalence of, 1139, 1313, 1339
types of, 1164
Obstructive sleep apnea (OSA)
bariatric surgery and, 1301

Orlistat
for obesity in adolescents, 1342
OSA. *See* Obstructive sleep apnea (OSA)

P

Peptide YY
bariatric surgery effects of, 1153
Pouch dilation
AGB and, 1256
Psychological disorders
bariatric surgery and, 1303–1304
Pulmonary embolism
LRNYGB and, 1212

Q

Quality of life
after bariatric surgery, 1330

R

REALIZE band, 1240
REE. *See* Resting energy expenditure (REE)
Renal disorders
bariatric surgery and, 1301–1302
Resting energy expenditure (REE), 1142–1143
Revisional bariatric surgery, **1353–1371**
adhesiolysis in, 1355
after AGB, 1363–1366
after failed restrictive procedures, 1361–1366
after VBG, 1361–1363
drains in, 1356
gastric stapling in, 1355
gastrostomy tube in, 1356
laparoscopy *vs.* open approach to, 1356
leak testing in, 1355–1356
loop gastric bypass conversion to RYGB, 1357–1358
malabsorption added to RYGB, 1359–1361
operative principles of, 1355–1356
overview of, 1353–1354
preoperative evaluation and testing in, 1354–1355
contrast upper GI study, 1354
dietary intake diary and nutritional counseling, 1354
esophageal manometry, 1354–1355
upper endoscopy, 1354
proximal RYGB revision, 1358–1359
RYGB revision, 1356–1357
Rimonabant
for obesity in adolescents, 1342
Robotics, 1381–1383

Roux-en-Y gastric bypass (RYGB)
AGB *vs.*
comparative effectiveness studies on, 1327–1328
loop gastric bypass conversion to, 1357–1358
LSG *vs.*
comparative effectiveness studies on, 1328–1329
malabsorption added to, 1359–1361
proximal
revision of, 1358–1359
revision of, 1356–1357
RYGB. *See* Roux-en-Y gastric bypass (RYGB)

S

Sexual disorders
bariatric surgery and, 1303–1304
Sibutramine
for obesity in adolescents, 1341
Single-incision laparoscopy, 1379–1380
Sleep apnea
obstructive
bariatric surgery and, 1301
Sleeve gastrectomy, **1265–1279**
complications of, 1272–1276
evolution of, 1195–1197
history of, 1195–1197, 1265
laparoscopic. *See* Laparoscopic sleeve gastrectomy (LSG)
mechanisms of action related to, 1271–1272
outcomes of, 1268–1271
technique, 1265–1268
weight loss due to, 1268–1271
Slippage/prolapse
AGB and, 1254–1256
Stenosis(es)
stomal
LRNYGB and, 1213
Stomach dilatation
bypassed
LRNYGB and, 1214
Stomal stenosis
LRNYGB and, 1213
Swedish Adjustable Band, 1240
Syndrome X, 1141–1142

T

TEE. *See* Total energy expenditure (TEE)
Thromboembolism
venous
LRNYGB and, 1226
Topiramate
for obesity in adolescents, 1342

Total energy expenditure (TEE), 1142–1143
Trans-oral endoscopic Restrictive Implant System, 1387–1388
Transoral gastroplasty system, 1387, 1388

U

Ulcer(s)
  marginal
    LRNYGB and, 1213–1214, 1231–1233
Upper endoscopy
  in revisional bariatric surgery evaluation, 1354

V

ValenTX endoscopically placed sleeve, 1385–1386
VBG. *See* Vertical banded gastroplasty (VBG)
Venous thromboembolism
  LRNYGB and, 1226
Vertical banded gastroplasty (VBG)
  history of, 1240
  revision after, 1361–1363
Vitamin deficiencies
  after LRNYGB, 1216–1218

W

Weight loss
  after AGB
    failure of, 1257–1258
  bariatric surgery and, 1317–1319
  inadequate
    after LRNYGB, 1214
  LAGB and, 1242–1243
  sleeve gastrectomy and, 1268–1271
Weight loss surgery. *See also specific types and* Bariatric surgery
  described, 1150–1157
  effectiveness of, 1150
  enteroencephalic endocrine axis communication pathways effects on, 1151
  enteroinsular axis effects on, 1154–1155
  ghrelin effects of, 1151–1152
  glucagon-like peptide-1 effects on, 1155
  glucose-independent insulinotropic peptide effects on, 1155
  incretin effect in, 1155–1157
  leptin effects of, 1154
  neuropeptide Y effects of, 1152–1153
  peptide YY effects of, 1153
  physiology of, **1139–1151**
Wound(s)
  LRNYGB-related
    complications of, 1214